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Abstract
Background
Mass administrations of antimalarial drugs (MDA) have reduced the incidence and preva-
lence of P. falciparum infections in a trial in the Greater Mekong Subregion. Here we assess
the impact of the MDA on P. vivax infections.
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Methods
Between May 2013 and July 2017, four villages in each Myanmar, Vietnam, Cambodia and
Lao PDR were selected based on high prevalence of P. falciparum infections. Eight of the
16 villages were randomly assigned to receive MDA consisting of three-monthly rounds of
three-day courses of dihydroartemisinin-piperaquine and, except in Cambodia, a single low-
dose of primaquine. Cross-sectional surveys were conducted at quarterly intervals to detect
Plasmodium infections using ultrasensitive qPCR. The difference in the cumulative inci-
dence between the groups was assessed through a discrete time survival approach, the dif-
ference in prevalence through a difference-in-difference analysis, and the difference in the
number of participants with a recurrence of P. vivax infection through a mixed-effect logistic
regression.
Results
3,790 (86%) residents in the intervention villages participated in at least one MDA round, of
whom 2,520 (57%) participated in three rounds. The prevalence of P. vivax infections fell
from 9.31% to 0.89% at month 3 but rebounded by six months to 5.81%. There was no evi-
dence that the intervention reduced the cumulative incidence of P.vivax infections (95%
confidence interval [CI] Odds ratio (OR): 0.29 to 1.36). Similarly, there was no evidence of
MDA related reduction in the number of participants with at least one recurrent infection
(OR: 0.34; 95% CI: 0.08 to 1.42).
Conclusion
MDA with schizontocidal drugs had a lasting effect on P. falciparum infections but only a
transient effect on the prevalence of P. vivax infections. Radical cure with an 8-aminoquino-
line will be needed for the rapid elimination of vivax malaria.
Introduction
Malaria transmission has fallen in the Greater Mekong Subregion (GMS) since the early 2000s.
P. falciparum infections have declined at a faster rate than P. vivax infections resulting in the
current dominance of P. vivax in most parts of the GMS [1]. The steady decline in P. falcipa-
rum transmission has stalled over the last years coinciding with the emergence and spread of
multidrug-resistant P. falciparum [1]. The spread of resistance is cause for international con-
cern, as the earlier spread of multidrug-resistant P. falciparum from Asia to sub-Saharan
Africa, had devastating public health consequences [2]. Particularly in areas of low malaria
transmission, mass antimalarial drug administrations (MDA) have the potential to accelerate
the elimination of malaria. The MDA described here resulted in a substantial reduction of P.
falciparum infections over a 12-month period [3].
P. vivax, in contrast to P. falciparum, has persistent liver stages (hypnozoites) which cause
relapse. Relapse patterns vary geographically. In southeast Asia, P. vivax tends to have short
relapse intervals [4]. Repeated relapses continue the transmission of vivax malaria and impact
adversely on health and quality of life. Multiple vivax relapses are a considerable burden in
children affecting growth, development and education [5]. Clearing hypnozoites requires a
radical cure with a course of 8-aminoquinolines, but this class of drugs is underutilized related
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to the risk of haemolysis in individuals with glucose-6 phosphate-dehydrogenase (G6PD)
deficiency.
Here we report a post hoc analysis of the concomitant effect of a MDA with dihydroartemi-
sinin-piperaquine (DP) plus a single low dose primaquine (SLDPQ) on the prevalence, inci-
dence, and frequency of recurrence of P. vivax infections in the GMS. SLDPQ is a potent P.
falciparum gametocytocide but has neither measurable activity against P. vivax hypnozoites
nor does it cause clinically relevant haemolysis in G6PD deficient people.
Methodology
Trial design
Pre-trial Plasmodium prevalence surveys using ultrasensitive PCR (uPCR) in 62 villages in the
four countries identified the villages with the highest P. falciparum prevalence. In each coun-
try, four villages with high P. falciparum prevalence and all-year access were included in the
study. Village pairs of similar size, access and P. falciparum prevalence were randomly allo-
cated to intervention or control using a computer-generated random sequence, except in
Myanmar where the drug allocation was decided by flipping a coin. Participants were enrolled
by specially trained field staff with the help of local health workers. Participants and field staff
were not blinded to the treatment allocation. However, laboratory personnel, who performed
the uPCR off-site, did not know which samples were from the intervention or control villages,
thereby reducing potential bias.
Study site
The study was conducted in rural Eastern Kayin (Karen) State of Myanmar; in two provinces
of Vietnam (Binh Phuoc and Ninh Thuan provinces: the former is in the Southeast region of
the country and shares a border with Cambodia, while the latter embraces the South Central
Coast of Vietnam); in Samlout District of Battambang province, Western Cambodia which
shares a border with Thailand), and in Nong Districts of Savannakhet province, southern Lao
PDR which shares a border with Vietnam. The location of the study sites is shown in Fig 1.
Detailed descriptions of the study sites have been published recently [6–9].
Participants
Every person in the selected villages was eligible to be included in the surveys if they gave
informed consent, were older than 6 months, were not ill at the time of the survey, and had no
known allergy to the study drugs. All pregnant women were excluded from the MDA in Cam-
bodia and Lao PDR, while in Myanmar and Vietnam only pregnant women in first trimester
were excluded. Breastfeeding women were invited to participate but did not receive SLDPQ.
Participants who experienced serious adverse events potentially related to study drugs or could
not tolerate the study drugs were withdrawn from the next MDA round but remained in the
study.
Intervention
The intervention consisted of three rounds of DP on three consecutive days. One SLDPQ
which clears P. falciparum gametocytes but has no effect on hypnozoites, was added to each
round of antimalarials. The treatment regimen was given at the start and then one and two
months after start of the study. SLDPQ was not administered in Cambodia for regulatory rea-
sons. A weight-based regimen containing a total dose of approximately 7 mg/kg dihydroarte-
misinin and 55 mg/kg piperaquine phosphate was used (Eurartesim1, Sigma Tau, Italy or
TME-Pv
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D-Artepp1, Guilin Pharmaceutical Co, Guilin, People’s Republic of China), while 0.25 mg
base/kg PQ was given as a single dose (Government Pharmaceutical Organization, Thailand).
The intervention was extended to the initial control villages after 12 months of follow-up,
except in Myanmar where the control villages received the intervention after nine months for
operational reasons (difficult access during rainy season).
Data collection and laboratory methods
The study started in Myanmar in May 2013, followed by Vietnam in November 2013, Cambo-
dia in July 2015 and Lao PDR in April 2016. Data were collected through community-wide
surveys at baseline, and then every three months. Surveys were preceded by a community cen-
sus to re-enumerate the study population and to provide intensive community engagement in
order to improve high coverage [10–14]. Information collected included demographics, bed-
net use, duration of stay in the forest, and adverse events. Malaria prevalence at each survey
was assessed by quantitative uPCR. 3 mL of blood was taken from participants older than 4
years old, and 0.5 mL from younger children. The blood samples were stored in cool boxes in
Fig 1. Map of the Greater Mekong Subregion. The areas highlighted in orange are study sites: Kayin (Karen) state, Myanmar; Battambang province, Cambodia;
Savannakhet Province, Lao PDR; Binh Phuoc and Ninh Thuan province, Vietnam.
https://doi.org/10.1371/journal.pone.0228190.g001
TME-Pv
PLOS ONE | https://doi.org/10.1371/journal.pone.0228190 February 5, 2020 4 / 16
the field for about 5–6 hours before being separated in the local laboratories and then kept in
-20˚C freezers. Samples from Myanmar, Cambodia, and Lao PDR were shipped on dried ice
to the Mahidol-Oxford Research Unit (MORU) in Bangkok, Thailand for uPCR while samples
collected in Vietnam were sent to the Oxford University Clinical Research Unit (OUCRU) in
Ho Chi Minh City, Vietnam. DNA was extracted from thawed packed red blood cells using
automated DNA extraction, dried in a centrifugal vacuum concentrator, and used as template
for PCR detection and quantification of Plasmodium. The methodology and performance
characteristics of the quantitative ultrasensitive PCR (uPCR) have been described previously
[15].
Sample size
The sample size described here was for assessing the impact of MDA on the P. falciparum elim-
ination. Four-village clusters per country, was chosen mainly for operational and practical rea-
sons. It is acknowledged that although the intracluster correlation coefficients (ICCs) were
generally very low in this region, there remains a problem of generalisability of findings when
such few numbers of clusters are used [16]. A formal sample size calculation suggested that 16
villages (8 villages in each arm) with a minimum of at least 152 individuals in each village
recruited and followed up would provide 80% power to detect a 95% fall in prevalence from a
10% initial prevalence, independently powered by country. This calculation assumes the high-
est ICC of 0.082 for P. falciparum baseline prevalence in the region that was observed in Laos
as a post-study analysis of the ICCs [16].
Outcomes
The aim of our post hoc analysis was to describe the impact of the MDA on the prevalence of
P. vivax infections at each quarterly survey, cumulative incidence of P. vivax parasitaemias
derived from uPCR results of the quarterly surveys, and frequency of recurrent P. vivax infec-
tions. Recurrent infections after treatment of the blood stage infection can be due to recrudes-
cence of a persistent infection, relapse due to activation of hypnozoites, or reinfection
following a new infectious mosquito bite.
Statistical analysis
The changes of prevalence of P. vivax infection at the separate surveys were assessed by a dif-
ference-in-difference (DiD) approach for which we fitted a logistic model that incorporated
effect modification between the intervention groups and the time period of the survey. We
assessed these differences between baseline and each follow-up time point (month 3, 6, 9, and
12) with the exception of month 12 data from Myanmar (where for logistic reasons the cross-
over MDA in control villages had to be conducted on M9 instead of M12). None of the param-
eters in the DiD analysis was constrained to zero. The cumulative uPCR-derived incidence of
P. vivax parasitaemias over the 12-month period was assessed using a survival analysis
approach in which participants were censored when diagnosed, lost to follow-up, end of the
observation period, which ever came first. The effect of the intervention on the incidence of P.
vivax parasitaemias was assessed through a discrete time survival approach using a pooled
mixed effects logistic regression analysis incorporating random effects for country and village.
A participant was considered to have a recurrent P. vivax infection if there were two or more
episodes with a positive uPCR result.
As consecutive positive uPCR tests could reflect continuous blood stage infection or fre-
quent relapses, we defined an episode in two ways. In the first approach, each positive uPCR
test was considered as a separate episode (i.e. relapse or reinfection). In the second approach,
TME-Pv
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consecutive positive uPCR results were considered to belong to the same continuous infection
(S1 Table). In two additional sensitivity analyses we considered a missing uPCR test results
either as positive or negative (S2–S7 Tables). We assessed the impact of MDA on the recur-
rence of P. vivax parasitaemias through mixed-effects logistic regression with random effects
for country and village.
All analyses used an individual weight that corrected for panel attrition during the observa-
tion period, and non-response at the separate surveys [17]. The panel-attrition weight is the
inverse of the probability of participating in all cross-sectional surveys given personal charac-
teristics and characteristics present during follow-up. The cross-sectional non-response weight
is the inverse of the probability of participating in a single survey, given the individual’s per-
sonal characteristics. Non-response weights were re-scaled to the original study sample to
avoid inflating the degrees-of-freedom. The final analysis weight is the product of all cross-sec-
tional non-response weights and the single panel-attrition weight. Personal characteristics
used in the weighting procedure included age, sex, occupation, resident status, length of stay
in the village, and village. Additional follow-up characteristics used in the panel-attrition
weight were a history of previous malaria, number of previous malaria episodes, previous posi-
tive rapid diagnostic test for malaria, and experience of adverse event in study. For both types
of weights, we used the chi-square automatic interaction detection (chaid) approach to derive
at groups of similar probability of participation [18]. We allowed the chaid procedure to
expand the number of groups if there would be at least 25 observations in the resulting groups.
Alpha-values for splitting and combining groups were set at 0.1. Inclusion of the predictors
was unordered, while continuous variables were grouped in three similar-sized groups using
tertiles. All statistical tests used an alpha level of 5%, below which statistical significance was
assumed. All analyses used the original treatment assignment groups and were performed in
STATA 14.1 (Stata Corp., College Station, Texas, USA).
Ethics statement
The studies were approved by the Cambodian National Ethics Committee for Health Research
(0029 NECHR, dated 04 Mar 2013), the Institute of Malariology, Parasitology and Entomology
in Ho Chi Minh City (185/HDDD dated 15 May 2013), the Institute of Malariology, Parasitol-
ogy and Entomology in Qui Nhon (dated 14 Oct 2013), the Lao National Ethics Committee
for Health Research (Ref No 013-2015/NECHR), Government of the Lao PDR and the Oxford
Tropical Research Ethics Committee (1015–13, dated 29 Apr 2013). Individual informed con-
sent was obtained from each participant or parent/guardian in the case on minors. A finger-
print was obtained for illiterate participants countersigned by a literate witness. (ClinicalTrials.
gov Identifier: NCT01872702)
Results
Participant characteristics were similarly distributed in intervention and control villages
(Table 1).
Coverage
At baseline survey (M0), there were 4,135 and 4,310 people living in the intervention and con-
trol villages while 3,333/4,135 (80%) and 3,426/4,310 (79%) participated in the study, respec-
tively. During three MDA rounds (M0, M1 and M2), 4,423 people were living in the
intervention villages. Of those, 3,790 (86%) completed at least one round (3 doses) of
DP-MDA and 2,520 (57%) completed 3 rounds (Fig 2).
TME-Pv
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Effect on prevalence
The prevalence of P. vivax parasitaemias decreased in both the intervention and control
villages during the 12-month follow-up. The prevalence dropped sharply from 9.31% at base-
line to 0.89% after three rounds of MDA at M3 follow-up (one month after the last MDA
round) but rebounded to 5.81% by M6 follow-up after which the difference in prevalence
between the intervention and the control villages was no longer statistically significant (coeffi-
cient (95%CI):-0.02 (-0.05, 0.003) (Fig 3). An analysis by country showed that the prevalence
of P. vivax parasitaemias rebounded in each study site except for Lao PDR where the P. vivax
prevalence dropped following the MDA and thereafter stayed low throughout the study period
(S1 Fig).
Table 1. Baseline sociodemographic, history of malaria and bednet use data of the control and intervention villages.
Characteristic Control (deferred MDA) villages Intervention (early MDA) villages Overall
Cumulative number of participants 4,734 4,246 8,980
Number of first-time participation, n (%)
Baseline 3,430 (72) 3,529 (83) 6,959 (77)
M03 558 (12) 316 (7) 874 (10)
M06 299 (6) 179 (4) 478 (5)
M09 238 (5) 130 (3) 368 (4)
M12 209 (4) 92 (2) 301 (3)
Age year, median (n, IQR) 20 (4,728, 8–35) 21 (4,241, 9–36) 20 (8,969, 9–36)
Sex, n (%)
Male 2,412 (51) 2,196 (52) 4,608 (51)
Female 2,322 (49) 2,050 (48) 4,372 (49)
Occupation, n (%)
Farmer 1,780 (38) 1,860 (44) 3,640 (41)
Child 413 (9) 266 (6) 679 (8)
Student 500 (11) 398 (9) 898 (10)
Others 194 (4) 225 (5) 419 (5)
Missing 1,847 (39) 1,497 (35) 3,344 (37)
History of malaria, n(%)
Yes 754 (16) 758 (19) 1,512 (17)
No history of malaria 1,910 (40) 1,492 (35) 3,402 (38)
Bednet use, n(%)
Regular 3,117 (66) 2,643 (62) 5,760 (64)
Irregular 470 (10) 555 (13) 1,025 (11)
Never use 90 (2) 122 (3) 212 (2)
Missing 1,057 (22) 926 (22) 1,983 (22)
Malaria infection by uPCR, n (%)
P.vivax 432 (9) 281 (7) 713 (8)
P. falciparum 180 (4) 154 (4) 334 (4)
P. vivax+P. falciparum 94 (2) 57 (1) 151 (2)
Unidentified Plasmodium 137 (3) 165 (4) 302 (3)
Negative 3,531 (75) 3,188 (75) 6,719 (75)
Not done 360 (8) 401 (9) 761 (8)
MDA, mass drug administration; IQR, interquartile range; uPCR, ultrasensitive quantitative PCR.
https://doi.org/10.1371/journal.pone.0228190.t001
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Fig 2. CONSORT flow diagram of MDA allocation and follow-up.
https://doi.org/10.1371/journal.pone.0228190.g002
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Effect on the incidence of P. vivax parasitaemias
The Kaplan-Meier survival curves (Fig 4) show a slower and lower cumulative uPCR-derived
incidence of P. vivax detected parasitaemias in the intervention group compared to the control
group. The uPCR-derived incidence of P. vivax detected parasitaemias in the control villages
by month 12 was highest in Vietnam, Lao PDR, and was lowest in Cambodia (S2 Fig). In Lao
PDR the uPCR-derived P. vivax incidence of detected parasitaemias remained very low in the
intervention villages over the follow-up period. In the other three sites, the incidence of
detected parasitaemias in intervention villages rapidly approached the incidence seen in the
control villages. There was no statistically significant evidence that the intervention reduced
the cumulative incidence of P.vivax infection (95% confidence interval [CI] Odds ratio (OR):
0.29 to 1.36) within a year follow-up. The cumulative incidence of detectable P. vivax parasi-
taemias was 37% lower in the intervention group compared to the control group. This differ-
ence did not reach statistical significance and there is therefore no evidence of an effect of the
intervention. This conclusion holds for each country separately (Fig 5). The intra-cluster cor-
relation coefficient (ICC) for the incidence of detectable P. vivax parasitaemias or village (as a
cluster), accounting for the random effect of country, was in the range from 0.17 to 0.63, esti-
mated at baseline and every 3 months up to month 12. The weighted-average ICC was 0.55
over the one-year follow-up.
Effect on recurrence of P. vivax parasitaemias and number of episodes
detected
The number of participants with recurrent parasitaemias was lower in the intervention villages
than in the control villages whether each positive uPCR tests was coded as a separate episode
Fig 3. Changes in the prevalence of P. vivax infection during 12-month follow-up in the control and intervention villages.
The month 12 data from Myanmar are not included because the cross-over MDA in the control villages had to be conducted
on M9 instead of M12. DiD, difference in difference, coefficient (95% confident interval).
https://doi.org/10.1371/journal.pone.0228190.g003
TME-Pv
PLOS ONE | https://doi.org/10.1371/journal.pone.0228190 February 5, 2020 9 / 16
Fig 4. Cumulative uPCR-derived incidences of P. vivax infection between intervention and control villages. The
month 12 data from Myanmar are not included because of logistic reasons, the cross-over MDA in the control villages
had to be conducted on M9 instead of M12.
https://doi.org/10.1371/journal.pone.0228190.g004
Fig 5. Forest plot of country odds ratios in the uPCR-derived incidence of P. vivax infections.
https://doi.org/10.1371/journal.pone.0228190.g005
TME-Pv
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(OR: 0.34) or consecutive positive uPCR tests were coded together as one continuous episode
(OR: 0.62). The estimates of the effect of MDA on recurrent parasitaemias varied-widely and
did not reach statistical significance overall (95%CI: 0.08–1.42, and 0.18–2.12, respectively)
(Table 2). Overall 809 (17.1%) of the participants in the control villages had at least one recur-
rent P. vivax episode compared to 562 (13.2%) in the intervention villages (Table 3). The sensi-
tivity analyses defining missing value to negative or to positive showed similar outcomes (S2 &
S3 Tables).
Discussion
This study found no evidence of a sustained effect of MDA with dihydroartemisinin-pipera-
quine on the prevalence of P. vivax infections over a one-year follow-up. The MDA reduced
the prevalence of P. vivax infections for three to six months after which a rebound in the preva-
lence of P. vivax parasitaemias was seen in all sites except for the sites in Lao PDR. The most
likely reason for the absence of a rebound in Lao PDR is the lower P. vivax incidence com-
pared to the other sites resulting in a lower risk for hypnozoite carriage, relapse and reinfec-
tion. Comparing P. vivax and P. falciparum prevalence changes between M3 and M6 suggests
that the prevalence of P. vivax increased faster than the P. falciparum prevalence. One explana-
tion for this observation could be that vivax hypnozoites fuel the speedy rebound of P. vivax
prevalence. An alternative perhaps complementary explanation could be that the P. vivax
transmission is higher at least in some of the study sites. MDA without a full course of 8-ami-
noquinolines clears only the blood stages of P. vivax and not the hypnozoites. As dihydroarte-
misinin-piperaquine clears P. vivax infections, recrudescent infections are unlikely the cause
for recurrent P.vivax infections. Relapses, and to a lesser degree reinfections, are the most
likely source for the observed P.vivax recurrences, and are a source of ongoing transmission
[19]. In SE Asia, P. vivax infections tend to relapse after short intervals (typically three weeks),
although the residual concentrations of slowly eliminated antimalarial drugs like piperaquine
Table 2. Multilevel logistic regression with random effect for country and village on P. vivax episode and analysis weight. (panel attrition and non-response).
Variable Control (deferred MDA) villages n = 4,734 Intervention (early MDA) villages n = 4,246 p-Value
Each positive test = one episode, n
Participants with recurrence, n (%) 408 (8.6) 183 (4.3)
Odds Ratio (95%CI) Ref. 0.34 (0.08–1.42) 0.138
Consecutive positive as one episode
Participants with recurrence, n (%) 170 (3.6) 113 (2.7)
Odds Ratio (95%CI) Ref. 0.62 (0.18–2.12) 0.443
MDA, mass drug administration; CI, confidence interval; Ref., reference
https://doi.org/10.1371/journal.pone.0228190.t002
Table 3. Comparison of the number of P. vivax episodes in the control and intervention villages.
No. episodes Each positive test = one episode Consecutive positive test = one episode
Control n = 4,734 Intervention n = 4,246 Control n = 4,734 Intervention n = 4,246
n (%) n (%) n (%) n (%)
0 3925 (82.9) 3684 (86.8) 3925 (82.9) 3684 (86.8)
1 401 (8.5) 379 (8.9) 639 (13.5) 449 (10.6)
2 194 (4.1) 124 (2.9) 160 (3.4) 108 (2.5)
3 136 (2.9) 48 (1.1) 10 (0.2) 5 (0.1)
4 62 (1.3) 10 (0.2)
5 16 (0.3) 1 (0)
https://doi.org/10.1371/journal.pone.0228190.t003
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have a prophylactic effect which can lead to prolonged intervals [20]. Following the treatment
of symptomatic infections with dihydroartemisinin-piperaquine, relapses emerge typically
around six weeks after treatment [21, 22]. The radical cure of P. vivax infections requires a 7-
or 14-day course of primaquine or single dose of tafenoquine. The SLDPQ aimed at blocking
transmission by clearing P. falciparum gametocytes which in contrast to P. vivax gametocytes
are resistant to schizontocidal drugs [23].
MDAs including radical cure with 8-aminoquinolines have been conducted in the former
Soviet republics, Afghanistan and North Korea, and are thought to have contributed to the
elimination of malaria from the USSR [24]. Mass primaquine administrations were used in
Azerbaijan in 1971 to eliminate P. vivax. Despite the high prevalence of G6PD deficiency, pri-
maquine administration was safe with few reported severe adverse events [25]. In China, pri-
maquine mass administrations were implemented at a large scale in “spring treatment”
involving over 200 million people at high risk for vivax malaria, and were effective in reducing
the incidence of P. vivax malaria [26]. MDA with a three day-course of chloroquine and pri-
maquine in Nicaragua showed a reduction of both P. falciparum and P. vivax, but P. vivax
returned, as in our study, to endemic levels within months after the MDA [27].
Our study has limitations: 1) The intervention, MDA with DP and SLDPQ, was designed to
eliminate P. falciparum and not P. vivax infections. Our post-hoc analyses describe the concurrent
effect of the intervention targeting P. falciparum on P. vivax. 2) Treating villages in the uninter-
rupted presence of infective reservoirs in the surrounding areas will inevitably result in reimporta-
tion of infections, as we observed in the return of P. falciparum infections after 12 months [3]. A
more regional approach to targeted malaria elimination including MDA would be required to
reduce the risk of re-importation of Plasmodium infections. 3) The prevalence estimate at month
12 could be an underestimated due to the absence of data from Myanmar (where for logistic rea-
sons the evaluation was conducted at month 9). In every site, except Laos, the prevalence of P.
vivax increased between month 6 and 12 in the intervention villages [6]. 4) Entomological aspects
were only evaluated in one study site [28]. Entomological data from more study sites may have
helped to gain further insights into malaria transmission dynamics. 5) We sampled study partici-
pants in quarterly intervals. More frequent sampling would have provided a better understanding
of the persistence of infections. The uPCR derived incidence of P. vivax parasitaemia reported in
our study is much higher than the incidence of clinical vivax malaria but allows us to estimate the
impact of the MDA on asymptomatic reservoir of P. vivax infections.
Our findings highlight the challenges but also suggest approaches to the elimination of all
malarias including vivax malaria. The mass administration of dihydroartemisinin-piperaquine
made a lasting and significant impact on P. falciparum infections [3], and on the P. falciparum
entomological inoculation rate [28]. To provide a sustained reduction of P. vivax transmission,
first and foremost radical cure with an 8-aminoquinoline is needed. Yet all 8-aminoquinolines
cause haemolysis in G6PD deficient individuals. There are several approaches for the treat-
ment of G6PD deficient individuals a) exclusion from the radical cure MDA b) use the one
weekly primaquine 0.75mg/kg regimen for 8 weeks c) an alternative primaquine dosing regi-
men with incremental, yet safe increase in dosing. A regimen allowing primaquine to be
stopped in case of symptoms or signs of haemolysis proved safe and effective without G6PD
testing in the former USSR [25]. Pregnant women and young children should not receive
8-aminoquinolines. Robust and accurate point-of-care tests for the diagnosis of G6PD defi-
ciency could play a pivotal role in the elimination of vivax malaria. A range of new diagnostic
tests is currently in development [29, 30]. Second, high participation in mass treatment pro-
grammes is critical in clearing asymptomatic reservoirs. More than 80% of residents are
thought having to participate in MDA to interrupt transmission but this estimate is not based
on empirical data [31]. Although the coverage of at least one MDA round reached that target,
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the coverage of three MDA rounds was low. Finally, understanding the reservoirs of the nearby
places and movement of people between places is essential in scaling up MDAs.
In conclusion, an MDA with schizontocidal and gametocytocidal medication for clearing
only blood-stage infection made a short lasting impact on P. vivax prevalence and a reduction
in recurrent infections but there no evidence of an effect on the long-term reduction of inci-
dence, prevalence, and number of recurrent P. vivax infections over 12-month follow-up. This
is in contrast to the impact of MDA on P. falciparum infections, where we showed a signifi-
cantly longer lasting impact [3]. The combination of effective blood schizontocidal and hypno-
zoiticidal drugs will be essential for the elimination of all malarias.
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